Edema News and Research

RSS
Edema means swelling caused by fluid in your body's tissues. It usually occurs in the feet, ankles and legs, but it can involve your entire body.
FDA approves new treatment for AML patients

FDA approves new treatment for AML patients

RetiPharma secures funding to develop new peptide drug for treating degenerative eye disorders

RetiPharma secures funding to develop new peptide drug for treating degenerative eye disorders

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Healogics to take part in campaign highlighting link between diabetes and chronic wounds

Healogics to take part in campaign highlighting link between diabetes and chronic wounds

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

TGen-UNM consortium awarded NIH grant to discover new treatments for diabetic blindness

TGen-UNM consortium awarded NIH grant to discover new treatments for diabetic blindness

Brigatinib drug may offer first-line treatment option for ALK-positive NSCLC

Brigatinib drug may offer first-line treatment option for ALK-positive NSCLC

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Biogen and Eisai announce results of LTE Phase 1b study of aducanumab for treating MCI

Biogen and Eisai announce results of LTE Phase 1b study of aducanumab for treating MCI

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Immediate compression therapy could cut risk of complications after deep-vein thrombosis

Immediate compression therapy could cut risk of complications after deep-vein thrombosis

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Study aims to investigate risk factors for PPCs in surgical patients with gastric cancer

Study aims to investigate risk factors for PPCs in surgical patients with gastric cancer

FDA approves new treatment for people with hairy cell leukemia

FDA approves new treatment for people with hairy cell leukemia

Novel treatment for hairy cell leukemia approved by FDA

Novel treatment for hairy cell leukemia approved by FDA